Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS 2330 (Tesofensine) in mild to moderate Alzheimer's disease
NCT00153010Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2003
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of tesofensine in Alzheimer's disease (AD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 20 weeks. Started Feb 2003; status: completed.
02
Drugs
tesofensine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00153010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153010.